{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:57:45Z","timestamp":1791107865136,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.dld.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T05:55:27Z","timestamp":1339566927000},"page":"1-7","source":"Crossref","is-referenced-by-count":23,"title":["Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials"],"prefix":"10.1016","volume":"45","author":[{"given":"Alessio","family":"Aghemo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2012.05.002_bib0005","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2012.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"Susser","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1053\/j.gastro.2010.08.031","article-title":"Colombo M. telaprevir for hepatitis C re-treatment: an open door on a long and winding road","volume":"139","author":"Aghemo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2012.05.002_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/eri.10.153","article-title":"Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients","volume":"9","author":"Burney","year":"2011","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"10.1016\/j.dld.2012.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2012.05.002_bib0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","article-title":"Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients","volume":"46","author":"Kieffer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.05.002_bib0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2012.05.002_bib0055","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.05.002_bib0060","first-page":"106A","article-title":"Telaprevir in combination with peginterferon alfa 2a and ribavirin for 24 or 48 weeks in treatment naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase III ILLUMINATE study","volume":"52","author":"Sherman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0070","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.05.002_bib0075","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.05.002_bib0080","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(11)60010-X","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"54","author":"Sullivan","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0085","first-page":"1347A","article-title":"Long-term follow-up analysis of the hepatitis C virus NS3 protease in patients treated with telaprevir or boceprevir\u2014a comparison between clonal and deep sequencing","volume":"54","author":"Susser","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0090","first-page":"377A","article-title":"Retreatment with telaprevir\/Peg-ifn\/Rbv after a short exposure to telaprevir in phase I studies: interim results from a phase IIIb rollover trial (c219)","volume":"54","author":"Sarrazin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jhep.2011.05.022","article-title":"Hyporesponsiveness to PegIFN\u03b12B plus ribavirin in patients with hepatitis C-related advanced fibrosis","volume":"56","author":"Prati","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.05.002_bib0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1478-3231.2011.02709.x","article-title":"Phase III results in genotype 1 na\u00efve patients: predictors of response with boceprevir and telaprevir combined with Pegylated interferon and Ribavirin","volume":"32","author":"Kwo","year":"2012","journal-title":"Liver International"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.05.002_bib0110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1478-3231.2011.02720.x","article-title":"Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders","volume":"32","author":"Forestier","year":"2012","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2012.05.002_bib0115","unstructured":"FDA telaprevir approval. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201917lbl.pdf."},{"key":"10.1016\/j.dld.2012.05.002_bib0120","first-page":"375A","article-title":"Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon\/ribavirin treatment failure: post hoc analysis of the phase III REALIZE study","volume":"54","author":"Berg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0125","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2011.03.002","article-title":"Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection","volume":"9","author":"Reiberger","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0130","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hep.23842","article-title":"Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C","volume":"52","author":"Roomer","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0135","doi-asserted-by":"crossref","unstructured":"Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with Peginterferon alfa\/Ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). Abstract EASL 2012.","DOI":"10.1016\/S0168-8278(12)60022-1"},{"key":"10.1016\/j.dld.2012.05.002_bib0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.dld.2012.05.002_bib0145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nature Genetics"},{"key":"10.1016\/j.dld.2012.05.002_bib0150","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C","volume":"52","author":"Urban","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0155","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C","volume":"140","author":"Dill","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2012.05.002_bib0160","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/S0168-8278(11)61371-8","article-title":"telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial","volume":"54","author":"Jacobson","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0165","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60014-7","article-title":"IL28B polymorphisms predicts virological response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy","volume":"54","author":"Poordad","year":"2011","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.05.002_bib0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2011.02712.x","article-title":"IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?","volume":"32","author":"Jensen","year":"2012","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2012.05.002_bib0175","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir\/PegIFN\/ribavirin: retrospective analysis of the REALIZE study","volume":"54","author":"Pol","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2010.10.032","article-title":"Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection","volume":"55","author":"Fried","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0265","doi-asserted-by":"crossref","first-page":"A934","DOI":"10.1016\/S0168-8278(12)60946-5","article-title":"Differences in HCV genotype 1 RVR rates among clinical trials in Europe depend on HCV-RNA assay sensitivity","volume":"56","author":"Vermehren","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2009.10.003","article-title":"Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis","volume":"52","author":"Moreno","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0195","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.05.002_bib0200","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0205","unstructured":"Parere dell\u2019Associazione Italiana per lo Studio del Fegato (AISF) sull\u2019uso della triplice terapia (PegIFN+Ribavirina+inibitore della proteasi di prima generazione) per il trattamento dei pazienti con epatite cronica da HCV genotipo 1. http:\/\/www.webaisf.org\/media\/14647\/position-paper-definitivo-26-01-12.pdf."},{"key":"10.1016\/j.dld.2012.05.002_bib0210","unstructured":"Prise de position de l\u2019Association Fran\u00e7aise pour l\u2019Etude du Foie (AFEF) sur les trith\u00e9rapies (Peg-IFN+ribavirine+inhibiteur de prot\u00e9ase) dans la prise en charge des malades atteints d\u2019h\u00e9patite chronique C."},{"key":"10.1016\/j.dld.2012.05.002_bib0270","doi-asserted-by":"crossref","DOI":"10.3109\/00365548.2012.669045","article-title":"Treatment of hepatitis C virus infection for adults and children: updated Swedish Consensus Recommendations","author":"Lagging","year":"2012","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1016\/j.dld.2012.05.002_bib0220","first-page":"1","article-title":"Expertenempfehlungen zur Triple-Therapie der HCV Infektion mit boceprevir und telaprevir","volume":"49","author":"Sarrazin","year":"2011","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"10.1016\/j.dld.2012.05.002_bib0225","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.2012.04992.x","article-title":"UK Consensus Guidelines for the use of protease inhibitors in genotype 1 chronic hepatitis C infected patients","volume":"35","author":"Ramachandran","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2012.05.002_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastrohep.2012.03.005","article-title":"Propuesta de Recomendaciones de la Sociedad Catalana de Digestivo en relacion al tratamiento triple del la hepatitis cronica C genotipo 1","author":"Bruguera","year":"2012","journal-title":"Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0235","first-page":"417A","article-title":"The cost-effectiveness of a telaprevir-inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the CC IL-28b polymorphism","volume":"54","author":"Gellad","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.05.002_bib0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1478-3231.2011.02707.x","article-title":"Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice","volume":"32","author":"H\u00e9zode","year":"2012","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2012.05.002_bib0245","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/S0168-8278(11)60479-0","article-title":"Anemia has no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in ADVANCE and ILLUMINATE phase 3 studies","volume":"54","author":"Sulkowski","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0250","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2011.05.014","article-title":"Second-wave protease inhibitors: choosing an heir","volume":"15","author":"Ciesek","year":"2011","journal-title":"Clinics in Liver Disease"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.05.002_bib0255","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2012.05.002_bib0260","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"New England Journal of Medicine"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865812001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865812001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T23:04:45Z","timestamp":1561849485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865812001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1590865812001843"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2012.05.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}